Regulated information



IBA SA - Erratum - Regulated information

November 28th 5:45 pm

Publication made under article 15 of the law of May 2, 2007 relating to the disclosure of major holdings in issuers whose shares are admitted to trading on a regulated market and containing various provisions (Belgian Gazette 12.VI.2007) (hereinafter, the "Law")

Under this provision:

"[...] the issuer publishes the total capital, the total number of securities conferring the right to vote and voting rights, as well as, by category, the number of securities conferring the right to vote and voting rights vote, at the latest at the end of each calendar month in which an increase or a decrease in these numbers occurred.

On each publication referred to in the first paragraph, the issuer also mentions, if applicable, the total number of bonds convertible into securities conferring the right to vote and rights materialized or not by securities to the subscription of securities conferring the right to vote not yet issued, the total number of voting rights that would result from the exercise of these conversion or subscription rights and the total number of shares without voting rights."

The following information are current as of November 09th ,2022

Nature of information		Remark
Amount of capital (EUR)	42.502.318,54	
Securities with voting rights =(A)	30.282.218	This is the basis for calculating the 30% threshold provided in article 5 of the takeover law of April 1, 2007 (Belgian Gazette 26.IV.2007)
Shares with voting rights	30.282.218	
Shares with loyalty voting right (section 28 of the articles of association) =(B)	8.120.827	
Existing voting rights =[A-B+(B*2)]	38.403.045	This is the denominator under which must be calculated the quota of voting rights that can give rise to notification in accordance with article 6 of the Law

Press release | November 28, 2022



Life, Science

info@iba-group.com | iba-worldwide.com

Press Release

Regulated information



Nature of information		Remark
Bonds convertible into shares (CB)	0	
Voting rights that would result of CB	0	
conversion		
Subscription rights (warrants) issued	20.000	
and exercisable		
Voting rights that would result of	20.000	
warrant conversion		
Statutory and legal thresholds	1%, 2%, 3%,	These are the thresholds under which
(section 35 of the articles of	4%, 5%, 7.5%,	the crossing, whether upward or
association)	10%, 15%, etc.	downward (including passive
	par tranche de	crossing), gives rise to notification in
	5%	accordance with section 6 or 18, §2, of
		the Law.

Contact person for threshold crossing notifications: shareholderrelations@iba-group.com.

Shares endowed with the right to vote in loyalty: registered shares recorded in the share register for at least two consecutive years in the name of their holder (section 28 of the articles of association, in accordance with section 7:53 of the Companies and Associations Code).

Following the introduction of the loyalty voting right by decision of the general meeting of March 10, 2020, the calculation method used by IBA to determine the number of shares with the loyalty voting right at any time is the LIFO method (last in, first out), namely: for the same registered shareholder, the shares which the latter most recently acquired are the first shares which will be deducted from his "basket" of registered shares if he transfer shares thereafter.

Statutory ceiling (section 7, paragraph 1, of the articles of association: "No shareholder may, with companies and persons related to him, participate in the voting at general meetings for a number of votes exceeding 35% of the votes attached to all of the shares with voting rights issued by the company"): currently 35% of 38.339.545, i.e. 13.418.840,8 votes.

ISIN Code: Euronext Brussels BE0003766806



Press release | November 28, 2022





2

info@iba-group.com | iba-worldwide.com

Press Release

Regulated information



About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,800 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com

For further information, please contact:

IBA

Marie Sirault Paralegal +32 491252480

marie.sirault@iba-group.com



